ZORGINSTITUUT NEDERLAND

Their core work

Zorginstituut Nederland is the Dutch National Health Care Institute, the public body responsible for determining which medical treatments, drugs, and technologies are included in the Netherlands' basic health insurance package. They conduct and commission Health Technology Assessments (HTA) to evaluate the clinical and cost-effectiveness of new therapies. In EU research projects, they contribute deep expertise in reimbursement decision-making, regulatory pathways, and the use of real-world evidence to inform coverage decisions — bridging the gap between clinical innovation and actual patient access.

What they specialise in

How they've shifted over time

Early H2020 participation (2015-2018) centred on regulatory frameworks, adaptive licensing pathways, and establishing multi-stakeholder collaboration models between regulators, HTA bodies, and payers — essentially building the governance architecture for faster drug access. By 2019-2024, the focus shifted decisively toward data-driven HTA: real-world data integration, evidence synthesis methods, EUnetHTA harmonisation, and personalised treatment assessment. This reflects a broader European trend away from process design toward evidence infrastructure.

Moving toward data-intensive, next-generation HTA methods that incorporate real-world evidence and personalised medicine — increasingly relevant as European HTA harmonisation (EU HTA Regulation) takes effect.

How they like to work

Zorginstituut Nederland participates exclusively as a consortium partner, never as coordinator — consistent with their role as a national authority contributing domain expertise rather than managing research projects. With 54 unique partners across 14 countries from just 3 projects, they operate in large, multi-country consortia typical of IMI and Horizon 2020 health policy initiatives. They are a trusted institutional voice that consortia invite for credibility with regulators and payers.

Despite only 3 projects, they have collaborated with 54 distinct partners across 14 countries, reflecting participation in large pan-European health policy consortia. Their network spans regulatory agencies, HTA bodies, pharmaceutical companies, and academic centres across Western and Northern Europe.

What sets them apart

As the Netherlands' official HTA and insurance package gatekeeper, Zorginstituut Nederland brings something few partners can: the perspective of the decision-maker who determines whether an innovation actually reaches patients and gets reimbursed. For any consortium developing health technologies, diagnostics, or treatment protocols, their involvement signals that real-world adoption pathways are being considered from the start. They are not a research lab — they are the bridge between innovation and market access.

Highlights from their portfolio

• HTx
  Largest project by funding (EUR 484,450), focused on next-generation HTA to support personalised medicine — directly aligned with the incoming EU HTA Regulation.
• ADAPT-SMART
  Multi-stakeholder initiative connecting regulators, HTA bodies, and payers to accelerate patient access to new therapies through adaptive pathways.